- Report
- July 2023
- 115 Pages
Global
From €3660EUR$3,850USD£3,130GBP
- Report
- January 2024
- 285 Pages
Global
From €9031EUR$9,500USD£7,723GBP
- Report
- June 2018
- 14 Pages
Global
From €9506EUR$10,000USD£8,130GBP
- Report
- March 2021
- 75 Pages
Global
€20914EUR$22,000USD£17,885GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2281EUR$2,400USD£1,951GBP
Neupro is a brand of central nervous system (CNS) drugs used to treat Parkinson's disease and restless legs syndrome. It is a dopamine agonist, meaning it works by activating dopamine receptors in the brain. Neupro is administered through a transdermal patch, which is applied to the skin and releases the drug over a period of time. The patch is designed to provide a steady, consistent dose of the drug throughout the day.
Neupro is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is currently marketed by UCB, a Belgian biopharmaceutical company. Other companies in the CNS drug market include AbbVie, GlaxoSmithKline, Merck, and Pfizer. Show Less Read more